英夫利昔单抗治疗实质型神经白塞综合征：病例系列和荟萃分析。

Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis.

机构信息

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.

Department of Neurology, Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, China.

出版信息

Clin Exp Rheumatol. 2024 Oct;42(10):2040-2048. doi: 10.55563/clinexprheumatol/5lnkd4. Epub 2024 May 15.

DOI:10.55563/clinexprheumatol/5lnkd4

PMID:38757293

Abstract

OBJECTIVES

This study aims to evaluate the efficacy and safety of infliximab (IFX) in patients with parenchymal neuro-Behçet's syndrome (p-NBS).

METHODS

We retrospectively analysed eleven p-NBS patients treated with IFX at our institution and combined them with studies from database searches for a meta-analysis. Pooled estimates of clinical response (complete and partial remission) and MRI improvement at months 3, 6, and 12 were calculated.

RESULTS

One patient achieved CR and the other ten patients achieved PR at our institution. 8 studies (77 patients) were included in the meta-analysis. At 3, 6, and 12 months, 97% (95%CI 61.9-100%), 89.6% (95%CI 45.9-100%), 100% (95%CI 96.0-100%) of patients showed clinical response and 100% (95%CI 89.7-100%), 89.1% (95% CI 26.3-100%), 99.5% (95% CI 96.0-100%) of patients showed radiological improvement, respectively. Severe adverse events were observed in 7 patients.

CONCLUSIONS

IFX was effective and relatively safe for p-NBS. Patients should be re-evaluated after 3 months of IFX to determine further therapy.

摘要

目的

本研究旨在评估英夫利昔单抗（IFX）治疗实质型神经白塞病（p-NBS）患者的疗效和安全性。

方法

我们回顾性分析了在我院接受 IFX 治疗的 11 例 p-NBS 患者，并结合数据库检索的研究进行荟萃分析。计算了第 3、6 和 12 个月时临床应答（完全和部分缓解）和 MRI 改善的汇总估计值。

结果

我院有 1 例患者达到 CR，10 例患者达到 PR。纳入荟萃分析的 8 项研究（77 例患者）。在第 3、6 和 12 个月时，97%（95%CI 61.9-100%）、89.6%（95%CI 45.9-100%）、100%（95%CI 96.0-100%）的患者出现临床应答，100%（95%CI 89.7-100%）、89.1%（95%CI 26.3-100%）、99.5%（95%CI 96.0-100%）的患者出现影像学改善。7 例患者出现严重不良事件。